Patents Examined by Marcos Sznaidman
  • Patent number: 9908884
    Abstract: The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: March 6, 2018
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Pasi Janne, Michael J. Eck, Wenjun Zhou
  • Patent number: 9889087
    Abstract: A method of improving cognition in a patient with Down syndrome, which entails intranasally administering one or more ?2-ADR agonists or pharmaceutically-acceptable salts of either or both to the patient in an amount and with a frequency effective to improve cognition of the patient as measured contextual learning tests.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: February 13, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ahmad Salehi, Brian Medina, Van Dang, Devsmita Das
  • Patent number: 9884070
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: February 6, 2018
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Sally J. Denardo, Gerald L. Denardo, Rodney L. Balhorn
  • Patent number: 9884809
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: February 6, 2018
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Patent number: 9884051
    Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: February 6, 2018
    Assignee: Dekk-Tec, Inc.
    Inventor: Lee Roy Morgan
  • Patent number: 9879058
    Abstract: The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: January 30, 2018
    Assignees: Universidad Andres Bello, Universiteit Gent, Katholieke Universiteit Leuven, Ku Leuven R & D
    Inventors: Jimmy Stehberg Liberman, Luc Gilbert Leybaert Sinia, Geert Albert Bultynck Demets, Mauricio Antonio Retamal Lucero, Fernando Danilo Gonzalez Nilo
  • Patent number: 9878980
    Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2(CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2(CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: January 30, 2018
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
  • Patent number: 9873700
    Abstract: Compounds active on protein kinases and methods for regulating protein kinase pathways are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: January 23, 2018
    Assignee: Plexxikon Inc.
    Inventors: Chao Zhang, Klaus-Peter Hirth, Prabha N. Ibrahim, Marika Nespi, Songyuan Shi, Wayne Spevak, Gaston G. Habets, Elizabeth A. Burton
  • Patent number: 9873704
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 23, 2018
    Assignee: AMGEN INC.
    Inventors: Minna Bui, Yi Chen, Timothy David Cushing, Jason A. Duquette, Benjamin Fisher, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Michael G. Johnson, Brian Lucas
  • Patent number: 9873682
    Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: January 23, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Gregory Notte
  • Patent number: 9868696
    Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 16, 2018
    Assignee: Bezwada Biomedial, LLC
    Inventor: Rao S Bezwada
  • Patent number: 9868729
    Abstract: Provided are methods of treating inflammatory disorders, autoimmune disorders, or a hematological malignancies using compounds of formula I and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof. Such disorders and conditions include leukemia and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 16, 2018
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Shawn M. Bauer, Anjali Pandey
  • Patent number: 9861598
    Abstract: A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: January 9, 2018
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Masahiro Inazuki
  • Patent number: 9856234
    Abstract: The present invention relates to a heterocyclic compound of the general formula (I) and their use and preparation, methods of making the compounds, compositions containing at least one of said compounds, and methods of treatment using at least one compound. In particular, compounds of the general formula (I) are useful for inhibiting glycogen synthase kinase 3 (GSK-3).
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: January 2, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Sean Colm Turner, Margaretha Henrica Maria Bakker, Kent D. Stewart
  • Patent number: 9849102
    Abstract: A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-? related activity level by more than 30% comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: December 26, 2017
    Assignee: ISIFER AB
    Inventor: Greta Edelstam
  • Patent number: 9839665
    Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 12, 2017
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Birgitta Leuthner
  • Patent number: 9827315
    Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: November 28, 2017
    Assignee: Themis Medicare Limited
    Inventors: Dinesh Shantilal Patel, Sachin Dinesh Patel, Shashikant Prabhudas Kurani, Madhavlal Govindlal Patel
  • Patent number: 9820935
    Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 21, 2017
    Assignee: EyeGate Pharmaceuticals, Inc.
    Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
  • Patent number: 9814724
    Abstract: The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect. The antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof. The present invention also provides a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; a method for inhibiting the growth of a tumor comprising the step of administering to a patient the aforementioned antitumor effect potentiator and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 14, 2017
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Junji Uchida, Koyo Shudo
  • Patent number: 9815834
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: November 14, 2017
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld